Selank (TP-7) is a synthetic heptapeptide derived from the tuftsin sequence and has been investigated in anxiety, neuropharmacology and brain-function research. Human studies exist, but the evidence base is limited and does not establish an FDA-approved Selank indication or universal human dosing protocol.
For concentration calculations, there is no scientifically established universal amount of bacteriostatic water that applies to every Selank vial. The resulting concentration is determined mathematically by the total peptide quantity divided by the liquid volume.
✓ Research Compound Human Research Available ⚠ Not FDA-Approved
Research Snapshot
Compound
Selank / TP-7
Class
Synthetic heptapeptide
Research Category
Neuropharmacology & anxiety research
U.S. Regulatory Status
Not FDA-approved
Human Evidence
Limited human studies
Vial Quantity
No authoritative standard established
Last Reviewed
September 10, 2026
How Much BAC Water for Selank?
There is no single universal BAC-water volume for Selank. The appropriate liquid volume depends on the actual quantity of peptide in the vial and the concentration required by a specific research protocol.
Mathematically, changing the amount of liquid changes the concentration while the total amount of peptide in the vial remains unchanged.
Concentration = Total Vial Quantity ÷ Liquid Volume
Selank Concentration Examples
Illustrative Vial Quantity
1 mL
2 mL
2.5 mL
3 mL
5 mL
5 mg Selank
5 mg/mL
2.5 mg/mL
2 mg/mL
1.67 mg/mL
1 mg/mL
10 mg Selank
10 mg/mL
5 mg/mL
4 mg/mL
3.33 mg/mL
2 mg/mL
Important: These are mathematical concentration examples only. They are not manufacturer-specific reconstitution instructions, clinical doses, FDA-approved dosages, or recommendations to use bacteriostatic water by a particular route.
How Much BAC Water Should Be Added to a 5 mg or 10 mg Selank Vial?
There is no authoritative universal Selank reconstitution volume that can be applied to every vial. A 5 mg vial, for example, mathematically produces 5 mg/mL if the final liquid volume is 1 mL and 1 mg/mL if the liquid volume is 5 mL.
Likewise, a 10 mg quantity produces 10 mg/mL at 1 mL, 5 mg/mL at 2 mL, 4 mg/mL at 2.5 mL, 3.33 mg/mL at 3 mL, and 2 mg/mL at 5 mL.
The important distinction: concentration mathematics tells you what concentration results from a known mass and known liquid volume. It does not tell you which concentration should be used in a human or laboratory protocol.
How Much BAC Water for Selank 5 mg?
For a hypothetical 5 mg Selank quantity, the mathematical relationship is:
1 mL 5 mg ÷ 1 mL = 5 mg/mL
2 mL 5 mg ÷ 2 mL = 2.5 mg/mL
5 mL 5 mg ÷ 5 mL = 1 mg/mL
How Much BAC Water for Selank 10 mg?
For a hypothetical 10 mg Selank quantity:
1 mL 10 mg ÷ 1 mL = 10 mg/mL
2 mL 10 mg ÷ 2 mL = 5 mg/mL
5 mL 10 mg ÷ 5 mL = 2 mg/mL
How Does BAC-Water Volume Change Selank Concentration?
Holding the peptide quantity constant, adding more liquid decreases the concentration, while adding less liquid increases it.
More liquid → lower mg/mL concentration.
Less liquid → higher mg/mL concentration.
The total peptide quantity does not change simply because the liquid volume changes.
Route, dose, formulation and concentration are separate variables.
How Do You Calculate Selank Concentration?
Divide the total Selank quantity by the liquid volume:
mg/mL = mg of Selank ÷ mL of liquid
What Is Selank?
Selank, also called TP-7, is a synthetic heptapeptide with the amino-acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was developed as an analogue of the naturally occurring immunomodulatory peptide tuftsin and has been investigated primarily in neuropharmacology and anxiety-related research.
PubMed-indexed literature describes Selank research involving anxiety-related behavior, neurochemical pathways, receptor interactions and human brain functional connectivity. A 2018 mechanistic review specifically examined possible GABAergic modulation and other molecular mechanisms. :contentReference[oaicite:2]{index=2}
AliasSelank, TP-7
Peptide classSynthetic heptapeptide
SequenceThr-Lys-Pro-Arg-Pro-Gly-Pro
CAS129954-34-3
Research focusNeuropharmacology, anxiety-related research, brain connectivity and neurochemical signaling
Research visual: Selank has been investigated in GABA-related molecular studies and human brain-connectivity research. This graphic is conceptual and does not represent a validated clinical mechanism.
How Selank Works
Selank's mechanism is not fully established. Experimental work has investigated several possible biological effects rather than identifying one universally accepted target.
Mechanistic Research
GABA-related signaling
Laboratory receptor studies have reported effects on GABA-related binding and proposed allosteric modulation. These findings do not establish a clinical therapeutic mechanism.
Human Research
Functional connectivity
A 2020 study examined resting-state brain connectivity in 52 healthy participants following Selank, Semax or placebo administration.
Preclinical
Neurochemical effects
Animal studies have examined neurotransmitter levels, learning, stress-related behavior and other CNS outcomes.
Evidence boundary: Molecular and animal findings can help generate hypotheses, but they should not automatically be translated into human efficacy, dose, safety or treatment recommendations.
What Is Selank Being Studied For?
Published research has investigated Selank in several areas of neuropharmacology. The strongest directly relevant human literature includes anxiety-related clinical research and experimental brain imaging.
Anxiety-related research: Small Russian clinical studies have compared Selank with benzodiazepine-class drugs in patients with anxiety-related disorders.
Brain functional connectivity: A placebo-controlled fMRI study examined short-term changes in resting-state connectivity after Selank administration.
GABAergic research: Laboratory experiments have investigated Selank's interaction with GABA-related receptor systems.
Learning and memory models: Animal research has evaluated behavioral learning and conditioned responses.
Neurochemical research: Animal studies have examined serotonin, dopamine and noradrenaline-related measures.
These research categories should not be interpreted as FDA-approved indications or as evidence that Selank is an established treatment for any of these conditions.
Human Clinical Research
Human Selank research exists, but it is limited compared with the evidence base for FDA-approved anxiolytic medications. A 2008 PubMed-indexed clinical study included 62 patients with generalized anxiety disorder and neurasthenia and compared Selank with medazepam. The authors reported anxiolytic effects, but the study was published in Russian and has important limitations when considered as evidence for modern regulatory approval. :contentReference[oaicite:3]{index=3}
A separate 2014 comparative study included 60 patients with phobic-anxiety and somatoform disorders and compared Selank with phenazepam. The PubMed record identifies it as a clinical trial and reports anxiolytic and mild nootropic effects, but this remains a relatively small study from the Russian literature. :contentReference[oaicite:4]{index=4}
In 2020, researchers studied 52 healthy participants using resting-state fMRI after Selank, Semax or placebo. The study found differences in functional connectivity involving the right amygdala and temporal regions. This was a mechanistic brain-imaging study, not a clinical efficacy trial for an anxiety disorder. :contentReference[oaicite:5]{index=5}
Human-dose caution: No FDA-approved Selank human dosage has been identified. Published indexed abstracts do not provide enough information to establish a universal clinical dose, and different formulations and routes cannot be treated as interchangeable.
Doses Studied in Published Research
The table below intentionally separates research observations from dosing recommendations. Where the authoritative indexed abstract does not provide the numerical human dose, it is reported as “not stated in indexed abstract” rather than being reconstructed from vendor or community sources.
These are research records, NOT BacScience dosage recommendations. Animal doses must not be converted directly into human doses.
Study
Population
Dose Studied
Route
Frequency
Duration
Key Finding
Human Zozulia et al., 2008 PMID 18454096
62 patients with generalized anxiety disorder and neurasthenia
Not stated in indexed abstract
Selank formulation described in the clinical literature; indexed abstract does not provide enough formulation detail
Not stated in indexed abstract
Study-dependent
Compared Selank with medazepam and reported anxiolytic effects in the studied population.
Human Medvedev et al., 2014 PMID 25176261
60 patients with phobic-anxiety and somatoform disorders
Not stated in indexed abstract
Not sufficiently detailed in indexed abstract
Study-dependent
Study-dependent
Reported anxiolytic and mild nootropic effects compared with phenazepam.
Human fMRI Panikratova et al., 2020 PMID 32342318
52 healthy participants
Numerical dose not stated in indexed abstract
Administration followed by resting-state fMRI
Acute experimental session
Measurements before and 5 / 20 minutes after administration
Differences in resting-state functional connectivity involving the right amygdala and right temporal regions were observed.
Why not list community dose numbers? Because a number repeated on peptide websites does not automatically become a clinically established dose. This page prioritizes source-verifiable research records.
Preclinical Research
Selank has also been studied extensively in laboratory and animal models. These studies provide mechanistic hypotheses but cannot be treated as human treatment evidence.
Rodent CNS models Studies have examined learning, memory, stress-related behavior and neurotransmitter systems.
Neurochemical research Animal experiments have measured serotonin, dopamine and noradrenaline-related changes.
GABA research Laboratory receptor studies have investigated possible concentration-dependent modulation of GABA-related binding.
For example, a mouse study reported administration of Selank at 300 µg/kg/day for five days by intranasal and intraperitoneal routes and examined behavioral and receptor-binding outcomes. This is an animal experiment and should not be converted into a human dose. :contentReference[oaicite:6]{index=6}
Another rat study administered 300 µg/kg intraperitoneally and examined behavior and brain monoamine levels following antenatal hypoxia. :contentReference[oaicite:7]{index=7}
Selank Research Reconstitution & Concentration
Reconstitution mathematics is independent from clinical dosing. If a vial contains a known mass of Selank and a researcher defines a liquid volume for an experimental formulation, the resulting concentration can be calculated directly.
Concentration (mg/mL) = Total Selank (mg) ÷ Liquid Volume (mL)
Worked Example: 5 mg Quantity
5 mg ÷ 1 mL = 5 mg/mL
5 mg ÷ 2 mL = 2.5 mg/mL
5 mg ÷ 5 mL = 1 mg/mL
Worked Example: 10 mg Quantity
10 mg ÷ 1 mL = 10 mg/mL
10 mg ÷ 2 mL = 5 mg/mL
10 mg ÷ 5 mL = 2 mg/mL
Research calculation only: The equation tells you the concentration produced by a known mass and known volume. It does not determine an appropriate route, formulation, dose, frequency, storage condition or human use.
BAC Water vs. Selank Concentration
Bacteriostatic water is a specific type of sterile diluent containing a preservative. Its presence does not create a universal Selank formulation standard.
In particular, the arithmetic table on this page should not be interpreted as evidence that BAC water is the appropriate diluent for every Selank formulation or route.
The vial's total peptide mass remains the same in the mathematical calculation.
Increasing liquid volume decreases the resulting mg/mL concentration.
Decreasing liquid volume increases the resulting mg/mL concentration.
A concentration is not the same thing as a clinical dose.
A published research dose is not automatically a reconstitution instruction.
A community protocol is not an FDA-approved dosage.
Selank is not an FDA-approved drug product in the United States. FDA's current compounding-safety material lists Selank acetate (TP-7) among substances previously placed in Category 2 but withdrawn after the nominator indicated that a different bulk substance was intended. FDA's listed safety concern for Selank acetate includes potential immunogenicity associated with aggregation and peptide-related impurities, along with insufficient information about human safety. :contentReference[oaicite:8]{index=8}
FDA also explains that bulk substances used for compounding must meet specific statutory and regulatory conditions under sections 503A or 503B. Inclusion, nomination or evaluation of a substance should not be interpreted as FDA approval of a drug product containing that substance. :contentReference[oaicite:9]{index=9}
Regulatory distinction:
FDA-approved dosage: No FDA-approved Selank dosage has been identified.
Human research: Small human studies have been published.
Preclinical research: Animal and laboratory studies provide additional mechanistic evidence.
Mathematical concentration: Can be calculated from mass and liquid volume.
Community protocol: Not equivalent to regulatory or clinical evidence.
Product identity, peptide purity, aggregation, impurities, sterility, formulation compatibility and route-specific safety are separate scientific questions that cannot be answered by concentration mathematics alone.
Frequently Asked Questions About Selank Reconstitution
How much BAC water should be added to Selank?
There is no universal Selank BAC-water volume established by an authoritative source. The mathematical volume required to obtain a particular concentration depends on the total Selank quantity and desired concentration. Product-specific formulation instructions, where applicable, take priority over generic calculations.
How much BAC water for 5 mg Selank?
As mathematical examples only, 5 mg in 1 mL equals 5 mg/mL, 5 mg in 2 mL equals 2.5 mg/mL, and 5 mg in 5 mL equals 1 mg/mL. These values do not constitute a recommended reconstitution protocol.
How much BAC water for 10 mg Selank?
Mathematically, 10 mg in 1 mL equals 10 mg/mL, 2 mL equals 5 mg/mL, and 5 mL equals 2 mg/mL. The appropriate formulation cannot be determined from mathematics alone.
What is the Selank concentration formula?
Concentration in mg/mL equals the total amount of Selank in milligrams divided by the liquid volume in milliliters.
Does adding more BAC water lower Selank concentration?
Yes. If the peptide quantity remains constant, increasing the liquid volume decreases the resulting mg/mL concentration.
Is Selank FDA-approved?
No FDA-approved Selank drug product or FDA-approved Selank dosage has been identified for the United States. FDA has separately evaluated Selank acetate in the context of bulk-compounding nominations and has described safety concerns and information gaps.
Does Selank have human research?
Yes. PubMed-indexed human studies include anxiety-related clinical research and a 2020 resting-state fMRI study involving 52 healthy participants. The overall evidence base remains limited compared with established FDA-approved therapies.
Does a published Selank dose equal a recommended dose?
No. A dose reported in a research study describes what was used in that specific experiment. It is not automatically a recommendation, FDA-approved dosage or universal protocol.
Can animal Selank doses be converted directly to humans?
No. Animal dose, exposure, absorption, metabolism and bioavailability can differ substantially from humans. Direct conversion can produce scientifically misleading results.
Is Selank concentration the same as Selank dose?
No. Concentration describes the amount of peptide per unit volume, such as mg/mL. A dose is an amount administered or studied under a specific protocol. The two concepts must not be treated as interchangeable.
Does BacScience recommend a human Selank dose?
No. BacScience's concentration examples are mathematical and educational. They do not prescribe a human dose, administration route or treatment protocol.
Zozulia AA et al. — Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008. PMID: 18454096. View PubMed record
2
Medvedev VE et al. — A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders. Zh Nevrol Psikhiatr Im S S Korsakova. 2014. PMID: 25176261. View PubMed record
3
Panikratova YR et al. — Functional Connectomic Approach to Studying Selank and Semax Effects. Doklady Biological Sciences. 2020. PMID: 32342318. View PubMed record
4
Vyunova TV et al. — Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein and Peptide Letters. 2018. PMID: 30255741. View PubMed record
5
Zozulya AA et al. — The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bulletin of Experimental Biology and Medicine. 2001. PMID: 11550013. View PubMed record
6
Vasil'eva EV et al. — Comparison of pharmacological effects of heptapeptide Selank after intranasal and intraperitoneal administration to BALB/c and C57BL/6 mice. Eksp Klin Farmakol. 2016. PMID: 29787664. View PubMed record
7
U.S. Food and Drug Administration — Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. FDA compounding safety information concerning Selank acetate (TP-7) and other bulk substances. View FDA resource
8
FDA — Bulk Drug Substances Used in Compounding. General FDA information concerning 503A and 503B bulk drug substance requirements. View FDA resource
Last Scientifically Reviewed
September 10, 2026 Scientific reviewer: [INSERT QUALIFIED REVIEWER NAME / CREDENTIALS] Content author: BacScience Research Content Team
Choosing a selection results in a full page refresh.
